Please assess the completion status of the following clinical trial:

Trial Title: Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~Patient level inclusion criterion~1. 18 years of age or older;~   Eye level inclusion criteria - at least one eye must meet all of the following conditions~2. Inactive or minimally active non-infectious anterior, intermediate, posterior or panuveitis, as defined by the Standardization of Uveitis Nomenclature (SUN) Working Group criteria as ≤ 0.5+ anterior chamber cells, ≤ 0.5+ vitreous haze grade and no active retinal/choroidal lesions for a minimum of 4 weeks;~3. Macular edema (ME) defined as the presence of macular thickness greater than the normal range for the OCT machine being used (see cut points below), regardless of the presence of cysts, following an intravitreal corticosteroid injection (≥ 4 weeks following intravitreal triamcinolone injection or ≥ 12 weeks following intravitreal dexamethasone implant injection);~   Greater than 300 μm for Zeiss Cirrus Greater than 320 μm for Heidelberg Spectralis Greater than 300 μm for Topcon SD OCT~4. Baseline fluorescein angiogram that, as assessed by the study ophthalmologist, is gradable for degree of leakage in the central subfield;~5. Best corrected visual acuity (BCVA) 5/200 or better;~6. Baseline intraocular pressure \> 5 mm Hg and ≤ 21 mm Hg (current use of ≤3 intraocular pressure-lowering medications and/or prior glaucoma surgery are acceptable (Note: combination medications, e.g., Combigan, are counted as two IOP-lowering medications);~7. Media clarity and pupillary dilation sufficient to allow OCT testing and assessment of the fundus.~Exclusion criteria:~Patient level exclusion criteria~1. History of infectious uveitis in either eye;~2. History of infectious scleritis of any type in either eye (Note: History of noninfectious scleritis that has been active in past 12 months is an eye-level exclusion -see #13 below);~3. History of keratitis (with the exception of keratitis due to dry eye) in either eye;~4. History of central serous retinopathy in either eye;~5. Active infectious conjunctivitis in either eye;~6. Oral prednisone dose \> 10 mg per day (or of an alternative corticosteroid at a dose higher than that equipotent to prednisone 10 mg per day) OR oral prednisone dose ≤ 10 mg per day at baseline that has not been stable for at least 4 weeks (note: if patient is off of oral prednisone at baseline (M01 study visit) dose stability requirement for past 4 weeks does not apply);~7. Systemic immunosuppressive drug therapy that has not been stable for at least 4 weeks (note: use of systemic methotrexate is acceptable as long as regimen has been stable for at least 4 weeks);~8. Use of oral acetazolamide or other systemic carbonic anhydrase inhibitor at baseline;~9. Known allergy or hypersensitivity to any component of the study drugs;~10. For women of childbearing potential: pregnancy, breastfeeding, or a positive pregnancy test; unwilling to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for duration of trial;~    Eye level exclusion criteria - at least one eye that meets all inclusion criteria cannot have any of the following conditions~11. History of infectious endophthalmitis;~12. History of severe glaucoma as defined by optic nerve damage (cup/disc ratio of ≥ 0.9 or any notching of optic nerve to the rim);~13. History of active noninfectious scleritis in past 12 months (Note: History of noninfectious scleritis is acceptable if the last episode of active scleritis resolved at least 12 months prior to enrollment);~14. Presence of an epiretinal membrane noted clinically or by OCT that per the judgment of study ophthalmologist may be significant enough to limit improvement of ME (i.e., causing substantial wrinkling of the retinal surface);~15. Torn or ruptured posterior lens capsule~16. Presence of silicone oil;~17. Ozurdex administered in past 12 weeks;~18. Anti-vascular endothelial growth factor (VEGF) agent, intravitreal methotrexate, or intravitreal/periocular corticosteroid administered in past 4 weeks;~19. Fluocinolone acetonide implant (Retisert) placed in past 3 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexamethasone intravitreal implant 0.7mg (Type: ACTIVE_COMPARATOR): Participants were randomized to a treatment group. A participant may have 1 or 2 eyes with macular edema (eligible eyes) receiving the same treatment.~Eligible eye(s) treated at study visit M01 (week 0).~Retreatment required at study visit M03 (8 weeks) if re-treatment criteria met.~Retreatment permitted at later time points if retreatment criteria met.~Re-treatment criteria:~1. Central subfield thickness greater than 1.1X upper limit of normal (330 μm for Zeiss and Topcon Spectral Domain (SD) Optical Coherence Tomography (OCT) and 352 μm for Heidelberg OCT) and/or cystoid space(s) within 1 mm central subfield.~2. IOP of \<25 mm Hg (treatment with ≤3 IOP-lowering agents permitted)~Minimum time between treatments: minimum target is 8 weeks after last injection but re-injection permitted as early as 51 days after last injection;
- Intravitreal methotrexate 400µg in 0.1mL (Type: ACTIVE_COMPARATOR): Participants were randomized to a treatment group. A participant may have 1 or 2 eyes with macular edema (eligible eyes) receiving the same treatment.~Eligible eye(s) treated at study visit M01 (week 0).~Retreatment required at M02 (4 weeks) and M03 (8 weeks) if retreatment criteria met.~Retreatment permitted at later time points if retreatment criteria met.~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection.
- Intravitreal ranibizumab 0.5mg in 0.05mL (Type: ACTIVE_COMPARATOR): Participants were randomized to a treatment group. A participant may have 1 or 2 eyes with macular edema (eligible eyes) receiving the same treatment.~Eligible eye(s) treated at study visits M01 (week 0), M02 (4 weeks), and M03 (8 weeks).~Retreatment permitted at M04 (12 weeks) and at later time points if retreatment criteria met.~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection.~Re-treatment permitted at later time points if re-treatment criteria met.

Based on this trial design, predict the completion outcome and termination type (if applicable).